Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy- results of a longitudinal study

Oral Oncology ◽  
2020 ◽  
Vol 109 ◽  
pp. 104856
Author(s):  
Silke Tribius ◽  
Henning Pazdyka ◽  
Pierre Tennstedt ◽  
Chia-Jung Busch ◽  
Henning Hanken ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Prognostic Factors ◽  
Longitudinal Study ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head

scholarly journals Radiotherapy for locally advanced head and neck cancer in elderly patients: results and prognostic factors a single cohort

2021 ◽  
Vol 26 (1) ◽  
pp. 12-19
Author(s):  
Gustavo Viani ◽  
Alexandre Faustion ◽  
Aniele Freitas Bendo Danelichen ◽  
Fernando Kojo Maatsura ◽  
Leonardo Vicente Fay Neves ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Prognostic Factors ◽  
Elderly Patients ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Single Cohort

Prognostic factors in patients with locally advanced head and neck cancer treated with concurrent radiochemotherapy

2015 ◽  
Vol 121 (3) ◽  
pp. 229-237 ◽  
Author(s):  
Davide Franceschini ◽  
Fabiola Paiar ◽  
Calogero Saieva ◽  
Pierluigi Bonomo ◽  
Benedetta Agresti ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Prognostic Factors ◽  
Head And Neck ◽  
Neck Cancer ◽  
Locally Advanced ◽  
Advanced Head ◽  
Concurrent Radiochemotherapy

scholarly journals Modified Weekly Cisplatin-Based Chemotherapy Is Acceptable in Postoperative Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Hsueh-Ju Lu ◽  
Chao-Chun Yang ◽  
Ling-Wei Wang ◽  
Pen-Yuan Chu ◽  
Shyh-Kuan Tai ◽  
...  
Keyword(s):  
Head And Neck Cancer ◽  
Prognostic Factors ◽  
Head And Neck ◽  
Neck Cancer ◽  
Concurrent Chemoradiotherapy ◽  
Locally Advanced ◽  
Common Adverse Effect ◽  
Advanced Head ◽  
Weekly Chemotherapy ◽  
Weekly Cisplatin

Background. Triweekly cisplatin-based postoperative concurrent chemoradiotherapy (CCRT) has high intolerance and toxicities in locally advanced head and neck cancer (LAHNC). We evaluated the effect of a modified weekly cisplatin-based chemotherapy in postoperative CCRT.Methods. A total of 117 patients with LAHNC were enrolled between December 2007 and December 2012. Survival, compliance/adverse events, and independent prognostic factors were analyzed.Results. Median follow-up time was 30.0 (3.1–73.0) months. Most patients completed the entire course of postoperative CCRT (radiotherapy ≥ 60 Gy, 94.9%; ≥6 times weekly chemotherapy, 75.2%). Only 17.1% patients required hospital admission. The most common adverse effect was grade 3/4 mucositis (28.2%). No patient died due to protocol-related adverse effects. Multivariate analysis revealed the following independent prognostic factors: oropharyngeal cancer, extracapsular spread, and total radiation dose. Two-year progression-free survival and overall survival rates were 70.9% and 79.5%, respectively.Conclusion. Modified weekly cisplatin-based chemotherapy is an acceptable regimen in postoperative CCRT for LAHNC.

Sign in / Sign up

Export Citation Format

Share Document